Search Press releases

8 Mar 2024

Bimekizumab 48-week Phase 3 analyses in moderate to severe hidradenitis suppurativa showed sustained improvements in skin pain and draining tunnel count

Read More
4 Mar 2024

UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases

Read More
28 Feb 2024

UCB on Growth Path for a Decade Plus

Read More
9 Feb 2024

Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024

Read More
6 Feb 2024

Transparency notification FMR LLC

Read More
8 Jan 2024

UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe